CN1221254C - 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂 - Google Patents

新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂 Download PDF

Info

Publication number
CN1221254C
CN1221254C CNB018131549A CN01813154A CN1221254C CN 1221254 C CN1221254 C CN 1221254C CN B018131549 A CNB018131549 A CN B018131549A CN 01813154 A CN01813154 A CN 01813154A CN 1221254 C CN1221254 C CN 1221254C
Authority
CN
China
Prior art keywords
receptor
stimulating agent
antagonist
pharmaceutical composition
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018131549A
Other languages
English (en)
Chinese (zh)
Other versions
CN1443162A (zh
Inventor
S·乔森
B·M·尼尔森
K·S·萨克里尔森
J·斯瓦腾格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1443162A publication Critical patent/CN1443162A/zh
Application granted granted Critical
Publication of CN1221254C publication Critical patent/CN1221254C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CNB018131549A 2000-07-21 2001-07-19 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂 Expired - Fee Related CN1221254C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE00027540 2000-07-21
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination

Publications (2)

Publication Number Publication Date
CN1443162A CN1443162A (zh) 2003-09-17
CN1221254C true CN1221254C (zh) 2005-10-05

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018131549A Expired - Fee Related CN1221254C (zh) 2000-07-21 2001-07-19 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂

Country Status (18)

Country Link
EP (1) EP1301476A1 (enExample)
JP (1) JP2004504376A (enExample)
KR (1) KR100845450B1 (enExample)
CN (1) CN1221254C (enExample)
AU (2) AU2001282734B2 (enExample)
BR (1) BR0112661A (enExample)
CA (1) CA2411192A1 (enExample)
EA (1) EA006604B1 (enExample)
HU (1) HUP0301346A3 (enExample)
IL (1) IL154057A0 (enExample)
MX (1) MXPA03000548A (enExample)
NO (1) NO20030304L (enExample)
NZ (1) NZ523216A (enExample)
PL (1) PL360309A1 (enExample)
SE (1) SE0002754D0 (enExample)
WO (1) WO2002008178A1 (enExample)
YU (1) YU2603A (enExample)
ZA (1) ZA200210234B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107628981A (zh) * 2017-10-31 2018-01-26 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP2005501019A (ja) * 2001-06-15 2005-01-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
RS20060035A (sr) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2020230B1 (en) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
HRP20140589T1 (hr) 2009-06-15 2014-08-01 Takeda Pharmaceutical Company Limited Derivati pirazinooksazepina
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107628981A (zh) * 2017-10-31 2018-01-26 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Also Published As

Publication number Publication date
MXPA03000548A (es) 2004-04-05
AU2001282734B2 (en) 2006-10-12
CN1443162A (zh) 2003-09-17
KR20030036599A (ko) 2003-05-09
SE0002754D0 (sv) 2000-07-21
WO2002008178A1 (en) 2002-01-31
EA200300183A1 (ru) 2003-08-28
KR100845450B1 (ko) 2008-07-10
EP1301476A1 (en) 2003-04-16
HUP0301346A2 (hu) 2003-08-28
CA2411192A1 (en) 2002-01-31
IL154057A0 (en) 2003-07-31
AU8273401A (en) 2002-02-05
ZA200210234B (en) 2004-03-18
PL360309A1 (en) 2004-09-06
NZ523216A (en) 2005-05-27
EA006604B1 (ru) 2006-02-24
HUP0301346A3 (en) 2005-05-30
NO20030304L (no) 2003-03-12
YU2603A (sh) 2006-05-25
HK1057536A1 (en) 2004-04-08
NO20030304D0 (no) 2003-01-20
JP2004504376A (ja) 2004-02-12
BR0112661A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
CN1221254C (zh) 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
US6489341B1 (en) Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
JP4204315B2 (ja) セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
US9616061B2 (en) Methods and compositions for sleep disorders and other disorders
ZA200104598B (en) 2,3,4a-tetrahydro-1H-pyrazino(1,2,-a)aquinoxalin-5(6H)one derivates being 5HT2c agonists.
CN1239482C (zh) 烟碱性受体激动剂的正调节剂
US6506753B2 (en) Methods of making and using N-desmethylzopiclone
TW201444552A (zh) 一種包含ａｍｐｋ激活劑及血清素活性製劑之醫藥組合物及其用途
CN1195350A (zh) 化合物
CN1201461A (zh) 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
JP2007500168A (ja) １−スルホニルインドール誘導体、それらの調製及び５−ｈｔ６リガンドとしてのそれらの使用
US20060019970A1 (en) Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
CN1742005A (zh) 吲哚基马来酰亚胺衍生物
AU775093B2 (en) 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives as ligands for serotonin receptors
CN100378108C (zh) 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
JP4455992B2 (ja) 治療薬剤として有用なセロトニン受容体親和性を有するアリールアルキル・インドール、その製造方法、並びにそれらを含む医薬組成物
KR101651933B1 (ko) 세로토닌 5-ｈｔ6 수용체의 2-아미노-3-설포닐-테트라하이드로-피라졸로[1,5-ａ]피리도-피리미딘 길항제, 이의 제조방법 및 이의 용도
CN1345725A (zh) 治疗慢性阻塞性肺部疾病的二氮杂䓬并吲哚
CN100339073C (zh) 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺
US6333345B1 (en) Methods of using and compositions comprising N-desmethylzolpidem
TW200815009A (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
HK1057536B (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
AU2018356556A1 (en) New alcoxyamino derivatives for treating pain and pain related conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20120719